Aso Y, Akazan H
Department of Urology, Faculty of Medicine, University of Tokyo, Japan.
Urol Int. 1992;49(3):125-9. doi: 10.1159/000282409.
A randomized controlled study was conducted in patients with superficial bladder cancer in order to investigate the safety of an orally administered (3 g/day) Lactobacillus preparation, biolactis powder (BLP), and its preventive effect on the recurrence after transurethral resection of the bladder tumor (TUR-Bt). Of 58 cases enrolled in the study 23 cases in the BLP group and 25 cases in the control group completed the study. There were no significant differences in the patient characteristics for the complete cases between the two groups. Comparison of the disease-free duration by the Kaplan-Meier method revealed that the 50% recurrence-free interval after TUR-Bt was prolonged by BLP treatment (350 days) to 1.8 times that in the control group (195 days). A significant difference between the groups was detected by the long-rank test (p = 0.03). No adverse side effect was observed. The results suggest that oral administration of BLP is useful for the prevention of the recurrence of superficial bladder cancer.
为了研究口服(3克/天)乳酸菌制剂、合生元粉(BLP)的安全性及其对膀胱肿瘤经尿道切除术后(TUR-Bt)复发的预防作用,对浅表性膀胱癌患者进行了一项随机对照研究。在纳入研究的58例患者中,BLP组的23例患者和对照组的25例患者完成了研究。两组完成病例的患者特征无显著差异。通过Kaplan-Meier方法比较无病生存期发现,TUR-Bt术后50%的无复发间隔时间通过BLP治疗(350天)延长至对照组(195天)的1.8倍。通过长秩检验检测到两组之间存在显著差异(p = 0.03)。未观察到不良副作用。结果表明,口服BLP有助于预防浅表性膀胱癌的复发。